JP2007513190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513190A5 JP2007513190A5 JP2006542888A JP2006542888A JP2007513190A5 JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5 JP 2006542888 A JP2006542888 A JP 2006542888A JP 2006542888 A JP2006542888 A JP 2006542888A JP 2007513190 A5 JP2007513190 A5 JP 2007513190A5
- Authority
- JP
- Japan
- Prior art keywords
- times per
- present
- per week
- factor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100022641 Coagulation factor IX Human genes 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 229960004222 factor ix Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52708903P | 2003-12-03 | 2003-12-03 | |
| US60/527,089 | 2003-12-03 | ||
| US53938704P | 2004-01-26 | 2004-01-26 | |
| US60/539,387 | 2004-01-26 | ||
| US59274404P | 2004-07-29 | 2004-07-29 | |
| US60/592,744 | 2004-07-29 | ||
| US61451804P | 2004-09-29 | 2004-09-29 | |
| US60/614,518 | 2004-09-29 | ||
| US62338704P | 2004-10-29 | 2004-10-29 | |
| US60/623,387 | 2004-10-29 | ||
| PCT/US2004/041070 WO2005055950A2 (en) | 2003-12-03 | 2004-12-03 | Glycopegylated factor ix |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513190A JP2007513190A (ja) | 2007-05-24 |
| JP2007513190A5 true JP2007513190A5 (enExample) | 2008-08-28 |
| JP4738346B2 JP4738346B2 (ja) | 2011-08-03 |
Family
ID=34682416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006542888A Expired - Fee Related JP4738346B2 (ja) | 2003-12-03 | 2004-12-03 | ＧｌｙｃｏＰＥＧ化された第ＩＸ因子 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1694315A4 (enExample) |
| JP (1) | JP4738346B2 (enExample) |
| KR (1) | KR101209111B1 (enExample) |
| AU (1) | AU2004296860B2 (enExample) |
| BR (1) | BRPI0417341A (enExample) |
| CA (1) | CA2549413A1 (enExample) |
| IL (1) | IL175661A0 (enExample) |
| MX (1) | MXPA06006023A (enExample) |
| NZ (1) | NZ546733A (enExample) |
| WO (1) | WO2005055950A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| CN102212019B (zh) | 2003-03-14 | 2015-05-27 | 蔚所番有限公司 | 支化水溶性聚合物及其缀合物 |
| WO2006127896A2 (en) * | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
| EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
| AU2014280936B2 (en) * | 2004-06-30 | 2016-12-15 | Nektar Therapeutics | Polymer-factor ix moiety conjugates |
| WO2006005058A2 (en) * | 2004-06-30 | 2006-01-12 | Nektar Therapeutics Al, Corporation | Polymer-factor ix moiety conjugates |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| CA2593682C (en) | 2005-01-10 | 2016-03-22 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090305967A1 (en) * | 2005-08-19 | 2009-12-10 | Novo Nordisk A/S | Glycopegylated factor vii and factor viia |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
| US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
| CA2665480C (en) * | 2006-10-04 | 2019-11-12 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| PT2101821E (pt) | 2006-12-15 | 2014-10-03 | Baxter Int | Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo |
| CN101796063B (zh) | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | 使用糖聚乙二醇化g‑csf的治疗方法 |
| AU2008245524A1 (en) * | 2007-04-26 | 2008-11-06 | Cnj Holdings, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
| AU2008311973B2 (en) * | 2007-10-15 | 2013-10-03 | Cangene Corporation | Human Factor IX variants with an extended half life |
| EP2568042A1 (en) * | 2007-12-27 | 2013-03-13 | Baxter International Inc. | Chemically modified factor IX |
| CN103497247A (zh) | 2008-02-27 | 2014-01-08 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
| RU2010146387A (ru) * | 2008-04-16 | 2012-05-27 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | Модифицированные полипептиды фактора ix и их применение |
| CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| SG178051A1 (en) | 2009-07-27 | 2012-03-29 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| SG178141A1 (en) | 2009-07-27 | 2012-03-29 | Baxter Int | Blood coagulation protein conjugates |
| IN2012DN00908A (enExample) * | 2009-07-31 | 2015-04-03 | Bayer Healthcare Llc | |
| WO2011064247A1 (en) | 2009-11-24 | 2011-06-03 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
| SG10201913700SA (en) | 2010-07-09 | 2020-03-30 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
| DK2654794T3 (da) | 2010-12-22 | 2020-06-08 | Baxalta GmbH | Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| EP3941509B1 (en) | 2019-03-19 | 2025-12-03 | CSL Innovation Pty Ltd | Factor ix variants and uses thereof in therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AU744303B2 (en) * | 1997-12-01 | 2002-02-21 | Neose Technologies, Inc. | Enzymatic synthesis of gangliosides |
| EP2305312B1 (en) * | 2001-10-10 | 2015-03-04 | ratiopharm GmbH | Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
-
2004
- 2004-12-03 EP EP04813394A patent/EP1694315A4/en not_active Withdrawn
- 2004-12-03 JP JP2006542888A patent/JP4738346B2/ja not_active Expired - Fee Related
- 2004-12-03 NZ NZ546733A patent/NZ546733A/en not_active IP Right Cessation
- 2004-12-03 CA CA002549413A patent/CA2549413A1/en not_active Abandoned
- 2004-12-03 WO PCT/US2004/041070 patent/WO2005055950A2/en not_active Ceased
- 2004-12-03 MX MXPA06006023A patent/MXPA06006023A/es active IP Right Grant
- 2004-12-03 AU AU2004296860A patent/AU2004296860B2/en not_active Ceased
- 2004-12-03 BR BRPI0417341-4A patent/BRPI0417341A/pt not_active Application Discontinuation
-
2006
- 2006-05-16 IL IL175661A patent/IL175661A0/en unknown
- 2006-05-30 KR KR1020067010603A patent/KR101209111B1/ko not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513190A5 (enExample) | ||
| Bąk et al. | Challenges and opportunities for celecoxib repurposing | |
| US8003696B2 (en) | Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain | |
| CN1296412A (zh) | 采用超级崩解剂的速溶efavirenz胶囊或片剂的制剂 | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| JP2019515908A5 (enExample) | ||
| DK1453487T3 (da) | Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud | |
| CA3162623A1 (en) | Aerosolization systems, methods, and apparatuses | |
| WO2006070325A3 (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| WO2022117221A1 (en) | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection | |
| HRP960070A2 (en) | Use of quinoxaline and protease inhibitors in a composition for the treatment of aids and/or hiv infections | |
| US11571455B2 (en) | Methods and compositions for treating alcoholic liver disease | |
| JP2009538935A5 (enExample) | ||
| CN101346137A (zh) | 含有孔布勒塔斯塔坦与抗癌剂的组合物 | |
| EP1996014B1 (en) | Composition for treating bacterial, viral, fungal diseases, inflammation and pain | |
| CN113365617B (zh) | 用于医学疾病治疗的一氧化碳前药 | |
| JP2008517977A5 (enExample) | ||
| JP2018123140A (ja) | 活性成分（ｉ）含有組成物及びその製造方法 | |
| Raij | Mechanisms of vascular injury: the emerging role of the endothelium. | |
| JP2016521760A (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| WO2007132280A1 (en) | Isatin and its derivatives for use as a medicament | |
| ATE284696T1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
| NO20013901L (no) | Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter | |
| CN1747726A (zh) | 一种用于治疗hiv－1和hiv－2的治疗性组合物 |